Supervisor Profiles 2019
PLEASE NOTE THAT FOR ENTRY IN 2020 YOU SHOULD VIEW DPHIL RESEARCH OPPORTUNITIES 2020. (Not all of the opportunities advertised for 2019 are available for 2020.)
Antoniades Group – Translational cardiovascular research: cross-talk between adipose tissue and the cardiovascular system in humans
We undertake translational research by moving from bench to bedside and vice versa; our main focus is the cross-talk between adipose tissue and the cardiovascular system.
Development of the hematopoietic/ immune system in the embryo
This laboratory studies the role of the innate immune system (monocytes / macrophages) on the progression and regression of atherosclerosis. Recent work (In revision) has shown how diabetes results in epigenetic changes in bone marrow progenitor cells that have important implications for atherosclerosis progression and, indeed, a range of common diseases.
Defining the function of new causal atherosclerosis genes from CAD GWAS loci using in vitro and in vivo models
Studying genetic variation in cardiomyopathy and coronary artery disease across the entire allele frequency spectrum in order to identify causative genes and susceptibility loci.
Using state-of-the-art laboratory and computational approaches to understand how mammalian genes are switched on and off during development and differentiation and how this goes awry in human genetic diseases.
Understanding the underlying causes and mechanistic basis for intrahepatic fat storage to identify ways of preventing and treating fatty liver disease.
Applying a wide range of genomics methods and technologies to understand how gene expression is regulated.
Identifying the mechanistic basis for site-specific fat storage to identify new ways of tackling the metabolic consequences of obesity.
Our group focuses on determining the factors which affect T cells both in the control of viral infection and in the development of cancer. Within the context of cancer we aim to identify the factors affecting anti-cancer efficacy. Our work on the T cell responses against viral infections led us to an anti-viral restriction factor, IFITM3, which is now the focus of our work on anti-viral responses.
Our group has conducted a series of international adjuvant trials of chemotherapy for colorectal cancer (Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 – 1557). In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy and evaluation of drug resistance (Orlando G. et al, (2016), Hum Mol Genet, 25, 2349 – 2359).
The Preventive Cardiology Research Group aims to improve how we identify and prevent heart disease in young people.
Studying key components of the creatine kinase system to understand how they contribute to the pathophysiology of ischaemic heart disease and chronic heart failure.
Understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. Our overarching aim is to improve the management of myeloproliferative neoplasms and related conditions through better monitoring and therapeutic targeting of malignant stem cell populations.
Understanding how epigenetics impacts gene regulation to develop new therapeutic strategies.
Using single cell biology and genetics to understand how hematopoietic stem cells normally sustain blood formation, and how this process is altered during ageing and when leukemia develops.